Current Allergy and Asthma Reports

, Volume 7, Issue 6, pp 436–443 | Cite as

Soluble CD14: Role in atopic disease and recurrent infections, including otitis media

Article
First Online:

Abstract

Soluble CD14 (sCD14) is a part of innate immunity that has been implicated in many diseases, including allergic diseases. However, many influencing factors and confounders, including gender-gene-environment interactions, may complicate interpretations of the observed associations to allergic diseases. In this paper, we review current literature describing the functions of sCD14 and its associations with common (recurrent) infections and with allergic diseases. Because sCD14 is involved with immunologic responses to infections, and exposure to microbial compounds is debated as a protective or a trigger factor for allergy development, these factors—which include genotypes, gender, age, microbial agents (from the environment and infection), and tobacco smoke—cannot be assessed independently. We conclude that confounding effects are important and must be considered to understand the role of sCD14 in allergic development.

Keywords

Atopic Dermatitis Respiratory Syncytial Virus Breast Milk Allergic Disease Allergy Clin Immunol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Labeta MO, Durieux JJ, Fernandez N, et al.: Release from a human monocyte-like cell line of two different soluble forms of the lipopolysaccharide receptor, CD14. Eur J Immunol 1993, 23:2144–2151.PubMedCrossRefGoogle Scholar
  2. 2.
    Blumenthal MN: New thoughts regarding the genetics of atopy. Am J Respir Crit Care Med 2004, 169:555–556.PubMedCrossRefGoogle Scholar
  3. 3.
    Kitchens RL, Thompson PA, Viriyakosol S, et al.: Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest 2001, 108:485–493.PubMedGoogle Scholar
  4. 4.
    Lien E, Aukrust P, Sundan A, et al.: Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood 1998, 92:2084–2092.PubMedGoogle Scholar
  5. 5.
    Wright SD, Ramos RA, Tobias PS, et al.: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249:1431–1433.PubMedCrossRefGoogle Scholar
  6. 6.
    Wurfel MM, Hailman E, Wright SD: Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med 1995, 181:1743–1754.PubMedCrossRefGoogle Scholar
  7. 7.
    Bas S, Gauthier BR, Spenato U, et al.: CD14 is an acute-phase protein. J Immunol 2004, 172:4470–4479.PubMedGoogle Scholar
  8. 8.
    Arias MA, Rey Nores JE, Vita N, et al.: Cutting edge: human B cell function is regulated by interaction with soluble CD14: opposite effects on IgG1 and IgE production. J Immunol 2000, 164:3480–3486.PubMedGoogle Scholar
  9. 9.
    Filipp D, Alizadeh-Khiavi K, Richardson C, et al.: Soluble CD14 enriched in colostrum and milk induces B cell growth and differentiation. Proc Natl. Acad Sci U S A 2001, 98:603–608.PubMedCrossRefGoogle Scholar
  10. 10.
    Rey Nores JE, Bensussan A, Vita N, et al.: Soluble CD14 acts as a negative regulator of human T cell activation and function. Eur J Immunol 1999, 29:265–276.PubMedCrossRefGoogle Scholar
  11. 11.
    Vercelli D, Baldini M, Stern D, et al.: CD14: a bridge between innate immunity and adaptive IgE responses. J Endotoxin Res 2001, 7:45–48.PubMedGoogle Scholar
  12. 12.
    Dentener MA, Bazil V, Von Asmuth EJ, et al.: Involvement of CD14 in lipopolysaccharide-induced tumor necrosis factor-alpha, IL-6 and IL-8 release by human monocytes and alveolar macrophages. J Immunol 1993, 150:2885–2891.PubMedGoogle Scholar
  13. 13.
    Antal-Szalmas P: Evaluation of CD14 in host defence. Eur J Clin Invest 2000, 30:167–179.PubMedCrossRefGoogle Scholar
  14. 14.
    Yu B, Hailman E, Wright SD: Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids. J Clin Invest 1997, 99:315–324.PubMedCrossRefGoogle Scholar
  15. 15.
    Pugin J, Heumann ID, Tomasz A, et al.: CD14 is a pattern recognition receptor. Immunity 1994, 1:509–516.PubMedCrossRefGoogle Scholar
  16. 16.
    Lauener RP, Goyert SM, Geha RS, Vercelli D: Interleukin 4 down-regulates the expression of CD14 in normal human monocytes. Eur J Immunol 1990, 20:2375–2381.PubMedCrossRefGoogle Scholar
  17. 17.
    Blais DR, Harrold J, Altosaar I: Killing the messenger in the nick of time: persistence of breast milk sCD14 in the neonatal gastrointestinal tract. Pediatr Res 2006, 59:371–376.PubMedCrossRefGoogle Scholar
  18. 18.
    Jones CA, Holloway JA, Popplewell EJ, et al.: Reduced soluble CD14 levels in amniotic fluid and breast milk are associated with the subsequent development of atopy, eczema, or both. J Allergy Clin Immunol 2002, 109:858–866.PubMedCrossRefGoogle Scholar
  19. 19.
    Rothenbacher D, Weyermann M, Beermann C, Brenner H: Breastfeeding, soluble CD14 concentration in breast milk and risk of atopic dermatitis and asthma in early childhood: birth cohort study. Clin Exp Allergy 2005, 35:1014–1021.PubMedCrossRefGoogle Scholar
  20. 20.
    Snijders BE, Damoiseaux JG, Penders J, et al.: Cytokines and soluble CD14 in breast milk in relation with atopic manifestations in mother and infant (KOALA study). Clin Exp Allergy 2006, 36:1609–1615.PubMedCrossRefGoogle Scholar
  21. 21.
    Espinoza J, Chaiworapongsa T, Romero R, et al.: Evidence of participation of soluble CD14 in the host response to microbial invasion of the amniotic cavity and intra-amniotic inflammation in term and preterm gestations. J Matern Fetal Neonatal Med 2002, 12:304–312.PubMedCrossRefGoogle Scholar
  22. 22.
    Roos T, Martin TR, Ruzinski JT, et al.: Lipopolysaccharide binding protein and soluble CD14 receptor protein in amniotic fluid and cord blood in patients at term. Am J Obstet Gynecol 1997, 177:1230–1237.PubMedCrossRefGoogle Scholar
  23. 23.
    Cauwels A, Frei K, Sansano S, et al.: The origin and function of soluble CD14 in experimental bacterial meningitis. J Immunol 1999, 162:4762–4772.PubMedGoogle Scholar
  24. 24.
    Dubin W, Martin TR, Swoveland P, et al.: Asthma and endotoxin: lipopolysaccharide-binding protein and soluble CD14 in bronchoalveolar compartment. Am J Physiol 1996, 270(5 Pt 1):L736–L744.PubMedGoogle Scholar
  25. 25.
    Hoheisel G, Zheng L, Teschler H, et al.: Increased soluble CD14 levels in BAL fluid in pulmonary tuberculosis. Chest 1995, 108:1614–1616.PubMedCrossRefGoogle Scholar
  26. 26.
    Lin B, Noring R, Steere AC, et al.: Soluble CD14 levels in the serum, synovial fluid, and cerebrospinal fluid of patients with various stages of Lyme disease. J Infect Dis 2000, 181:1185–1188.PubMedCrossRefGoogle Scholar
  27. 27.
    Nockher WA, Wick M, Pfister HW: Cerebrospinal fluid levels of soluble CD14 in inflammatory and non-inflammatory diseases of the CNS: upregulation during bacterial infections and viral meningitis. J Neuroimmunol 1999, 101:161–169.PubMedCrossRefGoogle Scholar
  28. 28.
    Striz I, Zheng L, Wang YM, et al.: Soluble CD14 is increased in bronchoalveolar lavage of active sarcoidosis and correlates with alveolar macrophage membrane-bound CD14. Am J Respir Crit Care Med 1995, 151(2 Pt 1):544–547.PubMedGoogle Scholar
  29. 29.
    Ward C, Walters EH, Zheng L, et al.: Increased soluble CD14 in bronchoalveolar lavage fluid of stable lung transplant recipients. Eur Respir J 2002, 19:472–478.PubMedCrossRefGoogle Scholar
  30. 30.
    Zdolsek HA, Jenmalm MC: Reduced levels of soluble CD14 in atopic children. Clin Exp Allergy 2004, 34:532–539.PubMedCrossRefGoogle Scholar
  31. 31.
    Lødrup Carlsen KC, Lovik M, Granum B, et al.: Soluble CD14 at 2 yr of age: gender-related effects of tobacco smoke exposure, recurrent infections and atopic diseases. Pediatr Allergy Immunol 2006, 17:304–312.PubMedCrossRefGoogle Scholar
  32. 32.
    O’Donnell AR, Toelle BG, Marks GB, et al.: Age-specific relationship between CD14 and atopy in a cohort assessed from age 8 to 25 years. Am J Respir Crit Care Med 2004, 169:615–622.PubMedCrossRefGoogle Scholar
  33. 33.
    Yaegashi Y, Shirakawa K, Sato N, et al.: Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother 2005, 11:234–238.PubMedCrossRefGoogle Scholar
  34. 34.
    Rahman SH, Salter G, Holmfield JH, et al.: Soluble CD14 receptor expression and monocyte heterogeneity but not the C-260T CD14 genotype are associated with severe acute pancreatitis. Crit Care Med 2004, 32:2457–2463.PubMedCrossRefGoogle Scholar
  35. 35.
    Meiler C, Muhlbauer M, Johann M, et al.: Different effects of a CD14 gene polymorphism on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection. World J Gastroenterol 2005, 11:6031–6037.PubMedGoogle Scholar
  36. 36.
    Hollak CE, Evers L, Aerts JM, van Oers MH: Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 1997, 23:201–212.PubMedCrossRefGoogle Scholar
  37. 37.
    Nockher WA, Wigand R, Schoeppe W, Scherberich JE: Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus. Clin Exp Immunol 1994, 96:15–19.PubMedCrossRefGoogle Scholar
  38. 38.
    Fernandez-Real JM, Lopez-Bermejo A, Castro A, et al.: Opposite relationship between circulating soluble CD14 concentration and endothelial function in diabetic and nondiabetic subjects. Thromb Haemost 2005, 94:615–619.PubMedGoogle Scholar
  39. 39.
    Karhukorpi J, Yan Y, Niemela S, et al.: Effect of CD14 promoter polymorphism and H. pylori infection and its clinical outcomes on circulating CD14. Clin Exp Immunol 2002, 128:326–332.PubMedCrossRefGoogle Scholar
  40. 40.
    Garty BZ, Monselise Y, Nitzan M: Soluble CD14 in children with status asthmaticus. Isr Med Assoc J 2000, 2:104–107.PubMedGoogle Scholar
  41. 41.
    Nielsen HG, Lyberg T: Long-distance running modulates the expression of leucocyte and endothelial adhesion molecules. Scand J Immunol 2004, 60:356–362.PubMedCrossRefGoogle Scholar
  42. 42.
    Martin AC, Laing IA, Zhang G, et al.: CD14 C-159T and early infection with Pseudomonas aeruginosa in children with cystic fibrosis. Respir Res 2005, 6:63.PubMedCrossRefGoogle Scholar
  43. 43.
    Guerra S, Lohman IC, Halonen M, et al.: Reduced interferon gamma production and soluble CD14 levels in early life predict recurrent wheezing by 1 year of age. Am J Respir Crit Care Med 2004, 169:70–76.PubMedCrossRefGoogle Scholar
  44. 44.
    Wuthrich B, Kagi MK, Joller-Jemelka H: Soluble CD14 but not interleukin-6 is a new marker for clinical activity in atopic dermatitis. Arch Dermatol Res 1992, 284:339–342.PubMedCrossRefGoogle Scholar
  45. 45.
    Martin AC, Laing IA, Khoo SK, et al.: Acute asthma in children: relationships among CD14 and CC16 genotypes, plasma levels, and severity. Am J Respir Crit Care Med 2006, 173:617–622.PubMedCrossRefGoogle Scholar
  46. 46.
    Virchow JC Jr, Julius P, Matthys H, et al.: CD14 expression and soluble CD14 after segmental allergen provocation in atopic asthma. Eur Respir J 1998, 11:317–323.PubMedCrossRefGoogle Scholar
  47. 47.
    Holmlund U, Hoglind A, Larsson AK, et al.: CD14 and development of atopic disease at 2 years of age in children with atopic or non-atopic mothers. Clin Exp Allergy 2003, 33:455–463.PubMedCrossRefGoogle Scholar
  48. 48.
    Alexis N, Eldridge M, Reed W, et al.: CD14-dependent airway neutrophil response to inhaled LPS: role of atopy. J Allergy Clin Immunol 2001, 107:31–35.PubMedCrossRefGoogle Scholar
  49. 49.
    Koppelman GH, Reijmerink NE, Colin SO, et al.: Association of a promoter polymorphism of the CD14 gene and atopy. Am J Respir Crit Care Med 2001, 163:965–969.PubMedGoogle Scholar
  50. 50.
    Keskin O, Birben E, Sackesen C, et al.: The effect of CD14-c159T genotypes on the cytokine response to endotoxin by peripheral blood mononuclear cells from asthmatic children. Ann Allergy Asthma Immunol 2006, 97:321–328.PubMedCrossRefGoogle Scholar
  51. 51.
    LeVan TD, Guerra S, Klimecki W, et al.: The impact of CD14 polymorphisms on the development of soluble CD14 levels during infancy. Genes Immun 2006, 7:77–80.PubMedCrossRefGoogle Scholar
  52. 52.
    Holt PG, Sly PD: Interactions between respiratory tract infections and atopy in the aetiology of asthma. Eur Respir J 2002, 19:538–545.PubMedCrossRefGoogle Scholar
  53. 53.
    Wennergren G, Kristjansson S: Relationship between respiratory syncytial virus bronchiolitis and future obstructive airway diseases. Eur Respir J 2001, 18:1044–1058.PubMedCrossRefGoogle Scholar
  54. 54.
    Matricardi PM, Ronchetti R: Are infections protecting from atopy? Curr Opin Allergy Clin Immunol 2001, 1:413–419.PubMedGoogle Scholar
  55. 55.
    Kurt-Jones EA, Popova L, Kwinn L, et al.: Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000, 1:398–401.PubMedCrossRefGoogle Scholar
  56. 56.
    Juntti H, Kokkonen J, Dunder T, et al.: Serum concentrations of interferon-gamma and intercellular adhesion molecule-1 eight years after an early respiratory syncytial virus infection. Clin Exp Allergy 2005, 35:59–63.PubMedCrossRefGoogle Scholar
  57. 57.
    Faden H: The microbiologic and immunologic basis for recurrent otitis media in children. Eur J Pediatr 2001, 160:407–413.PubMedCrossRefGoogle Scholar
  58. 58.
    Yang IA, Savarimuthu S, Kim ST, et al.: Gene-environmental interaction in asthma. Curr Opin Allergy Clin Immunol 2007, 7:75–82.PubMedCrossRefGoogle Scholar
  59. 59.
    Jackola DR, Basu S, Liebeler CL, et al.: CD14 promoter polymorphisms in atopic families: implications for modulated allergen-specific immunoglobulin E and G1 responses. Int Arch Allergy Immunol 2006, 139:217–224.PubMedCrossRefGoogle Scholar
  60. 60.
    Gereda JE, Klinnert MD, Price MR, et al.: Metropolitan home living conditions associated with indoor endotoxin levels. J Allergy Clin Immunol 2001, 107:790–796.PubMedCrossRefGoogle Scholar
  61. 61.
    Lapa e Silva JR, Possebon DS, Lefort J, Vargaftig BB: Endotoxins, asthma, and allergic immune responses. Toxicology 2000, 152:31–35.PubMedCrossRefGoogle Scholar
  62. 62.
    Cook DG, Strachan DP: Health effects of passive smoking-10: summary of effects of parental smoking on the respiratory health of children and implications for research. Thorax 1999, 54:357–366.PubMedGoogle Scholar
  63. 63.
    Strachan DP, Cook DG: Health effects of passive smoking. 4. Parental smoking, middle ear disease and adenotonsil-lectomy in children. Thorax 1998, 53:50–56.PubMedCrossRefGoogle Scholar
  64. 64.
    Nouri-Shirazi M, Guinet E: Evidence for the immunosuppressive role of nicotine on human dendritic cell functions. Immunology 2003, 109:365–373.PubMedCrossRefGoogle Scholar
  65. 65.
    Skold CM, Lundahl J, Hallden G, et al.: Chronic smoke exposure alters the phenotype pattern and the metabolic response in human alveolar macrophages. Clin Exp Immunol 1996, 106:108–113.PubMedCrossRefGoogle Scholar
  66. 66.
    Hockertz S, Emmendorffer A, Scherer G, et al.: Acute effects of smoking and high experimental exposure to environmental tobacco smoke (ETS) on the immune system. Cell Biol Toxicol 1994, 10:177–190.PubMedCrossRefGoogle Scholar
  67. 67.
    Choudhry S, Avila PC, Nazario S, et al.: CD14 tobacco gene-environment interaction modifies asthma severity and immunoglobulin E levels in Latinos with asthma. Am J Respir Crit Care Med 2005, 172:173–182.PubMedCrossRefGoogle Scholar
  68. 68.
    Tan CY, Chen YL, Wu LS, et al.: Association of CD14 promoter polymorphisms and soluble CD14 levels in mite allergen sensitization of children in Taiwan. J Hum Genet 2006, 51:59–67.PubMedCrossRefGoogle Scholar
  69. 69.
    Savilahti E, Siltanen M, Kajosaari M, et al.: IgA antibodies, TGF-beta1 and-beta2, and soluble CD14 in the colostrum and development of atopy by age 4. Pediatr Res 2005, 58:1300–1305.PubMedCrossRefGoogle Scholar
  70. 70.
    Laitinen K, Hoppu U, Hamalainen M, et al.: Breast milk fatty acids may link innate and adaptive immune regulation: analysis of soluble CD14, prostaglandin E2, and fatty acids. Pediatr Res 2006, 59:723–727.PubMedCrossRefGoogle Scholar
  71. 71.
    Vidal K, Donnet-Hughes A, Granato D: Lipoteichoic acids from Lactobacillus johnsonii strain La1 and Lactobacillus acidophilus strain La10 antagonize the responsiveness of human intestinal epithelial HT29 cells to lipopolysaccharide and gram-negative bacteria. Infect Immun 2002, 70:2057–2064.PubMedCrossRefGoogle Scholar
  72. 72.
    Labeta MO, Vidal K, Nores JE, et al.: Innate recognition of bacteria in human milk is mediated by a milk-derived highly expressed pattern recognition receptor, soluble CD14. J Exp Med 2000, 191:1807–1812.PubMedCrossRefGoogle Scholar
  73. 73.
    Baveye S, Elass E, Fernig DG, et al.: Human lactoferrin interacts with soluble CD14 and inhibits expression of endothelial adhesion molecules, E-selectin and ICAM-1, induced by the CD14-lipopolysaccharide complex. Infect Immun 2000, 68:6519–6525.PubMedCrossRefGoogle Scholar
  74. 74.
    Lundell AC, Andersson K, Josefsson E, et al.: Soluble CD14 and CD83 from human neonatal antigen-presenting cells are inducible by commensal bacteria and suppress allergen-induced human neonatal Th2-differentiation. Infect Immun 2007, 75:4097–4104.PubMedCrossRefGoogle Scholar
  75. 75.
    Dunstan JA, Roper J, Mitoulas L, et al.: The effect of supplementation with fish oil during pregnancy on breast milk immunoglobulin A, soluble CD14, cytokine levels and fatty acid composition. Clin Exp Allergy 2004, 34:1237–1242.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Department of Pediatrics, Division of Woman and ChildUllevål University HospitalOsloNorway

Personalised recommendations